All In Biotech

Drug Trial Radar · NCT04239625

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Dec 20, 2019

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Lead sponsor
Alkeus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jan 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 8 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this open-label, multicenter study is to determine the long-term safety, pharmacokinetics and effects of ALK-001 (C20-D3-retinyl acetate) on the progression of Stargardt disease. This study is an extension of NCT02402660 and enrolls participants who are at least 8 years old. Enrollment is by invitation only. Funding Source - FDA OOPD

Conditions

  • Stargardt Disease
  • Stargardt Macular Degeneration
  • Stargardt Macular Dystrophy
  • Autosomal Recessive Stargardt Disease 1 (ABCA4-related)

Interventions

  • ALK-001Drug

    Oral administration of a pill for up to 24 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of ALK-001 assessed by incidence and/or clinically-significant changes of a combination of ocular and non-ocular adverse eventsTime frame: From baseline to 24 months
  2. Pharmacokinetic profile of ALK-001 derived from the concentrations of ALK-001 and metabolites in plasmaTime frame: Up to 24 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Alkeus Site

    Phoenix, Arizona

  • Alkeus Site

    Los Angeles, California

  • Alkeus Site

    Aurora, Colorado

  • Alkeus Site

    Gainesville, Florida

  • Alkeus Site

    Indianapolis, Indiana

  • Alkeus Site

    Grand Rapids, Michigan

  • Alkeus Site

    Westbury, New York

  • Alkeus Site

    Silverdale, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.